ALKS SEC Filings, Earnings & Splits

Alkermes entered into a confidential settlement and license agreement with Teva resolving a patent infringement lawsuit over Teva's ANDA for a generic version of Alkermes' LYBALVI. Under the agreement, Teva receives a limited license to launch its generic product in the U.S. beginning November 12, 2039 (or May 12, 2040 with pediatric exclusivity), and the parties filed a stipulation to dismiss the litigation with prejudice.

Alkermes plc furnished an 8-K announcing its financial results for the three and nine months ended September 30, 2026, along with a related press release and investor presentation.

Alkermes plc filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue from key products such as VIVITROL, LYBALVI, and VUMERITY, as well as the impact of the Avadel Pharmaceuticals acquisition and related financing arrangements.

Alkermes plc announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, a novel orexin 2 receptor agonist for ADHD.

Alkermes plc appointed Anne C. Whitaker to its board of directors, increasing board size from 10 to 11 members, effective September 14, 2026.